Great response Jad! Here it is for everyone else:
"You seem to have left out that six analysts either maintained or upgraded Insmed after the results, that the sp has moved back up three days in a row, that Arikace was deemed to be comparable to TOBI, that Arikace is a once a day dosing vs twice per day for TOBI and that TOBI users fail to dose twice per day at a rate of 30% to 40%. In their comparison trial TOBI users were forced to dose twice per day. The trial was not reflective of actual use but optimum use - and they were head to head anyway. In addition the beneficial effects of Arikace grew stronger over time while the beneficial effect of TOBI dropped to zero. The Company also announces that the U.S. Food and Drug Administration (FDA) designated ARIKACE as a Qualified Infectious Disease Product (QIDP) for the treatment of Non-Tuberculous Mycobacteria (NTM) lung infections. Additionally, the FDA granted Fast Track designation to ARIKACE for the treatment of NTM. There is no other treatment for NTM in existence today. You might want to consider publishing the entire story rather than this half #$%$ analysis. We'll see you at $25 per share by yearend or sooner. Then you can eat crow publicly."
It's really interesting. I watched 11 thumbs down come up in a period of about 12 minutes. I think that someone actually has at least 10 ids that they use to diss people. It's either a pretty warped human being or someone who's paid to be a warped human being. Either way, the party is now over for these folks and we are about to finally, after almost a decade, get to the end of the rainbow.
Terry must operate with a few computers from his basement office. You got to give him credit, he probably negotiated another $0.25 per thumbs down on every post made that is in contrast to what his bosses intentions are.
I wonder if Terry gets one and half times as much for holiday work!